Cargando…

Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy

Tumor microenvironment inflammation contributes to the proliferation and survival of malignant cells, angiogenesis, metastasis, subversion of adaptive immunity, and reduced treatment response. We aimed to evaluate the early predictive and prognostic significance of markers of systemic inflammation i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohlendorf, Fiona, Werner, Rudolf A., Henkenberens, Christoph, Ross, Tobias L., Christiansen, Hans, Bengel, Frank M., Derlin, Thorsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000284/ https://www.ncbi.nlm.nih.gov/pubmed/33809226 http://dx.doi.org/10.3390/diagnostics11030504

Ejemplares similares

Assessment of γ-H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors
por: Derlin, Thorsten, et al.
Publicado: (2021)

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
por: Liberini, Virginia, et al.
Publicado: (2020)

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
por: Camus, Baptiste, et al.
Publicado: (2021)

Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
por: Kipnis, Sarit T., et al.
Publicado: (2021)

Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy
por: Henkenberens, Christoph, et al.
Publicado: (2020)

Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors
por: Grey, Neil, et al.
Publicado: (2022)

Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE
por: Prétot, Dominique, et al.
Publicado: (2023)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
por: van der Zwan, W. A., et al.
Publicado: (2018)

Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under (177)Lu-PSMA-617 Radioligand Therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

Personalized prediction of mode of cardiac death in heart failure using supervised machine learning in the context of cardiac innervation imaging
por: Werner, Rudolf A., et al.
Publicado: (2020)

Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy
por: Widjaja, Liam, et al.
Publicado: (2022)

The Prognostic Value of Liquid Biopsies for Benefit of Salvage Radiotherapy in Relapsed Oligometastatic Prostate Cancer
por: Bogdanova, Natalia V., et al.
Publicado: (2022)

MicroRNA analysis of gastroenteropancreatic neuroendocrine tumors and metastases
por: Zimmermann, Nadine, et al.
Publicado: (2018)

Nuclear survivin is a prognosticator in gastroenteropancreatic neuroendocrine neoplasms: a meta-analysis
por: Krieg, Sarah, et al.
Publicado: (2022)

Prognostic impact of p16 and p21 on gastroenteropancreatic neuroendocrine tumors
por: LIU, SHUZHENG, et al.
Publicado: (2013)

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors
por: Kunz, Pamela L, et al.
Publicado: (2010)

Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment
por: Díez, Marc, et al.
Publicado: (2013)

Endoscopic Ultrasound in Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Michelle Kang
Publicado: (2012)

Medical Treatment of Gastroenteropancreatic Neuroendocrine Tumors
por: Rinke, Anja, et al.
Publicado: (2012)

Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Mafficini, Andrea, et al.
Publicado: (2019)

Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias
por: Sharma, Rohini, et al.
Publicado: (2021)

Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma
por: Mollazadegan, Kazhan, et al.
Publicado: (2021)

An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
por: Fang, Jiayun M, et al.
Publicado: (2022)

Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors
por: Crabtree, Judy S.
Publicado: (2022)

Advances in the imaging of gastroenteropancreatic neuroendocrine neoplasms
por: Ramachandran, Anupama, et al.
Publicado: (2022)

Mechanisms of Resistance in Gastroenteropancreatic Neuroendocrine Tumors
por: Shi, Chanjuan, et al.
Publicado: (2022)

Liver transplantation in gastroenteropancreatic neuroendocrine tumors
por: Fernandes, Eduardo de Souza M., et al.
Publicado: (2023)

Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors
por: McClellan, Kristen, et al.
Publicado: (2022)

Deepening of response to prostate-specific membrane antigen ligand-targeted radioligand therapy beyond end of treatment
por: Derlin, Thorsten, et al.
Publicado: (2021)

Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia
por: Dizdar, Levent, et al.
Publicado: (2016)

Clinicopathological features and prognostic factors associated with gastroenteropancreatic mixed neuroendocrine non-neuroendocrine neoplasms in Chinese patients
por: Huang, Yu-Chen, et al.
Publicado: (2021)

Gastroenteropancreatic neuroendocrine tumors in children and young adults
por: Khanna, Geetika, et al.
Publicado: (2007)

Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors
por: Öberg, Kjell
Publicado: (2012)

Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models
por: Kawasaki, Kenta, et al.
Publicado: (2018)

Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors
por: Cives, Mauro, et al.
Publicado: (2020)

Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot
por: Fernandez, Cornelius J, et al.
Publicado: (2021)

Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor
por: Asbach, Stefan, et al.
Publicado: (2017)

Distinct Expression Patterns of VEGFR 1-3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Supporting Clinical Relevance, but not a Prognostic Factor
por: Bösch, Florian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bcjqhp25nbm8se6ar99dstt521